drugs
Roche boosts oncology portfolio with $1.7bn acquisition
December 22, 2017Medical Communications, Sales and Marketing Roche, biotech, drugs, ignyta, pharma, pharmaceutical
Roche has announced that it will buy Ignyta, a San Diego-based biotech that has a pipeline of oncology drugs, for …
Eisai and Biogen Alzheimer’s drug stumbles at P2
December 21, 2017Medical Communications, Research and Development Biogen, Eisai, biotech, drugs, pharma, pharmaceutical
Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …
The rare disease climate in Europe
December 21, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, rare disease
Continuing on from this week’s earlier feature on the rare disease situation in the US, Pharmafile moves its attention onto …
MSD and Pfizer receive approval for combo diabetes therapy
December 21, 2017Sales and Marketing MSD, Pfizer, biotech, diabetes, drugs, pharma, pharmaceutical
MSD (known as Merck in North America) and Pfizer have announced that their sodium-glucose co-transporter 2 (SGLT2) inhibitor has received …
Death in trial blackens AbbVie’s positive rheumatoid arthritis data
December 21, 2017Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the …
J&J struck by €25m fine over fentanyl pain patch
December 20, 2017Research and Development, Sales and Marketing Johnson & Johnson, biotech, drugs, fentanyl, pharma, pharmaceutical
Johnson & Johnson has been fined by France’s competition authority, Autorité de la Concurrence, after it alleges the company had …
Genentech seals deal with DiCE Molecules
December 20, 2017Research and Development, Sales and Marketing DiCE, Genentech, Sanofi, biotech, drugs, pharma, pharmaceutical
Genentech has followed in the footsteps of its parent company by signing a drug discovery agreement with DiCE Molecules. The …
Spark gains approval for gene therapy, paving way for first $1m treatment
December 20, 2017Research and Development, Sales and Marketing Spark Therapeutics, biotech, drugs, gene therapy, pharma, pharmaceutical
The FDA handed approval to Spark Therapeutics’ gene therapy for an inherited eye disorder, making it the first treatment of …
Boehringer scoops schizophrenia candidates for €627.5m
December 19, 2017Manufacturing and Production, Sales and Marketing Autifony, Boehringer Ingelheim, biotech, drugs, pharma, pharmaceutical
Boehringer Ingelheim has moved early to secure an exclusive option on Autifony’s lead candidate for the treatment of schizophrenia, AUT00206, …
100,000 vacancies contribute to NHS crisis
December 19, 2017Manufacturing and Production, Medical Communications NHS, UK, biotech, drugs, nurses, pharma, pharmaceutical
Warning shots have been fired by both the General Medical Council (GMC) and the Labour Party about the recruitment issues …
Novartis snaps up Priority Review Voucher for $130m
December 18, 2017Manufacturing and Production, Sales and Marketing Novartis, Ultragenyx, biotech, drugs, pharma, pharmaceutical
Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million …
Rare disease medicines access faces a perfect storm
December 18, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, rare disease
With access to rare disease treatments coming under increasing attention, both in the EU and the US, Pharmafile.com took the …
Apotex founder found dead at home
December 18, 2017Medical Communications, Sales and Marketing Apotex, biotech, drugs, pharma, pharmaceutical
Apotex, the world’s seventh largest generics manufacturer, has lost its Chairman and founder, after Barry Sherman and his wife, Honey, …
Keytruda falls hard at gastric cancer hurdle
December 18, 2017Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical
There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …
New PARP inhibitor hits UK market, offering distinct advantage
December 18, 2017Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical
Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
